期刊
PROSTATE
卷 77, 期 15, 页码 1468-1477出版社
WILEY
DOI: 10.1002/pros.23407
关键词
Dunning rat prostate tumors; immunohistochemistry; prostate cancer death; SIGLEC1; tumor-draining lymph nodes
资金
- Cancerfonden [130293]
- Vetenskapsradet [Co257301]
- Vasterbotten Lans Landsting
- Lion's Cancer Research Foundation (Umea University)
- Swedish Cancer Society
- Swedish Research Council
- County of Vasterbotten
BackgroundTumor-derived antigens are captured by CD169(+) (SIGLEC1(+)) sinus macrophages in regional lymph nodes (LNs), and are presented to effector cells inducing an anti-tumor immune response. Reduced CD169 expression in pre-metastatic regional LNs is associated with subsequent metastatic disease and a poor outcome in several tumor types, but if this is the case in prostate cancer has not been explored. MethodsCD169 expression was measured with immunohistochemistry in metastasis-free regional LNs from 109 prostate cancer patients treated with prostatectomy (January 1996 to April 2002). Possible associations of CD169 expression with PSA-relapse, prostate cancer death, Gleason score, and other clinical data were assessed using Kaplan-Meier survival- and Cox regression analysis. In addition, the Dunning rat prostate tumor model was used to examine CD169 expression in pre-metastatic LNs draining either highly metastatic MatLyLu- or poorly metastatic AT1-tumors. ResultsIn patients with low CD169 immunostaining in metastasis-free regional LNs, 8 of the 27 patients died from prostate cancer compared with only three of the 82 patients with high immunostaining (P<0.001). CD169 expression in regional LNs was not associated with PSA-relapse. Rats with highly metastatic tumors had decreased CD169 immunoreactivity in pre-metastatic regional LNs compared with rats with poorly metastatic tumors. ConclusionLow expression of CD169 in metastasis-free regional LNs indicates a reduced anti-tumor immune response. If verified in other studies, CD169 expression in regional LNs could, in combination with other factors, potentially be used as a marker of prostate cancer aggressiveness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据